137864-44-9

Usage

Uses

Used in Pharmaceutical Industry:
L-Valine, N-(1-oxopentyl)-N-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-, phenylmethyl ester is used as a building block for the synthesis of pharmaceutical compounds due to its complex structure and multiple functional groups. Its versatility allows for the development of new drugs with potential therapeutic applications.
Used in Materials Science:
In the field of materials science, L-Valine, N-(1-oxopentyl)-N-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-, phenylmethyl ester can be used as a component in the development of novel materials with specific properties. Its unique structure may contribute to the creation of materials with improved characteristics for various applications.
Used in Organic Chemistry:
L-Valine, N-(1-oxopentyl)-N-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-, phenylmethyl ester serves as a valuable intermediate in organic synthesis. Its presence of various functional groups makes it a useful compound for the synthesis of other complex organic molecules, potentially leading to the discovery of new chemical reactions and products.

Upstream product

• 894793-37-4 benzyl N-[4-(5,5-dimethyl-[1,3,2]dioxaborinan-2-yl)phenyl-4-yl-methyl]-N-pentanoyl-L-valinate 
• 143945-72-6 N-trityl-5-(2-bromophenyl)tetrazole 
• 638-29-9 n-valeryl chloride 
• 2462-34-2 L-valine benzyl ester hydrochloride 
• 124750-51-2 N-(triephenylmethyl)-5-<4'-(bromomethyl)-biphenyl-2-yl>tetrazole 

Downstream Products

• 137862-53-4 N-pentanoyl-N-[[2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]-methyl]-(L)-valine 
• 137863-20-8 (S)-N-(1-benzyloxycarbonyl-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amine 
• 596-31-6 methoxytriphenylmethane 
• 783369-52-8 N-pentanoyl-N-(4-(2-(1-trityl-1H-tetrazol-5-yl)phenyl)phenyl)methyl-L-valine 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS AND INTERMEDIATES THEREOF

The present invention relates to an improved process for the preparation of angiotensin receptor antagonists and intermediates thereof. Particularly the present invention relates to an improved process for the preparation of N-(1-oxopentyl)-N-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-L-valine of Formula 1 via a phosphite salt of Formula-4.H3PO3 preferably a phosphite salt of Formula-4′.H3PO3

AN IMPROVED PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS AND INTERMEDIATES THEREOF.

The present invention relates to an improved process for the preparation of angiotensin receptor antagonists and intermediates thereof. Particularly the present invention relates to an improved process for the preparation of N-(l-oxopentyl)-N-[[2''-(lH-tetrazoI-5-yl) [1, 1 ''-biphenyl]-4-yl] methyl]-L- valine of Formula (1) Formula-1 Formula-4.H3P03 via a phosphite salt of Formula-4.H3P03 preferably a phosphite salt of Formula-4''.H3P03 Ph3C N-[2''-1 -triphenylmethyl-tetra zol-5-yl)biphenyl-4-yl)methyl ]-(L)-Valine Benzyl ester H3P03 salt Formula-4''.H3P03 salt.

PROCESS FOR PREPARING VALSARTAN

An N-[(2'-(1-triphenyl methyl tetrazole-5-yl) biphenyl]-4-yl] methyl]-L-valine benzyl ester organic salt of formula (IVA) wherein A represents an organic carboxylic acid, a process for its preparation and its use in the synthesis of valsartan or salts thereof.

INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF VALSARTAN

It comprises a preparation process of Valsartan from new salts of Valsartan having the tetrazole moiety protected with a protective group. The process leads to the elimination of the typical impurities due to the preparation process while avoiding its rac

INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST

It comprises new substituted 4-valinylmethylphenyl boronic acids and their derivatives and also its preparation process. It also comprises a preparation process of Valsartan from such intermediates. The process comprises the reaction of the new 4-valinylmethylphenyl boronic compounds with a (halophenyl)tetrazole compound which proceeds with high yields. The process is particularly advantageous in its practical industrial realization because it avoids the use of azide derivatives and also the use of expensive biphenyl intermediates.

A METHOD OF PREPARATION OF N-(1-OXOPENTYL)-N-[[2'-(1H-TETRAZOL-5-y1) [1,1'-BIPHENYL] -4-y1]METHYL]-L-VALINE (VALSARTAN)

From the starting 4-bromomethyl-2'-(1-triphenylmethyltetrazol-5-yl)biphenyl, N-[(2'-(1-triphenylmethyl-tetrazol-5-yl)biphenyl-4-yl)methyl]-(L)-valine benzyl ester of formula 7 is obtained via a reaction with L-valine benzyl ester, and is converted to vals

ACYL COMPOUNDS

Compounds of the formula STR1 in which R 1 is an aliphatic hydrocarbon radical which is unsubstituted or substituted by halogen or hydroxyl, or a cycloaliphatic or araliphatic hydrocarbon radical; X 1 is CO, SO 2, or--O--C(=O)--with the carbon atom of the carbonyl group being attached to the nitrogen atom shown in formula I; X 2 is a divalent aliphatic hydrocarbon radical which is unsubstituted or substituted by hydroxyl, carboxyl, amino, guanidino or a cycloaliphatic or aromatic radical, or is a divalent cycloaliphatic hydrocarbon radical, it being possible for a carbon atom of the aliphatic hydrocarbon radical to be additionally bridged by a divalent aliphatic hydrocarbon radical; R. sub.2 is carboxyl which, if desired, is esterified or amidated, substituted or unsubstituted amino, formyl which, if desired, is acetalized, 1H-tetrazol-5-yl, pyridyl, hydroxyl which, if desired, is etherified, S(O) m--R where m is 0, 1 or 2 and R is hydrogen or an aliphatic hydrocarbon radical, alkanoyl, unsubstituted or N-substituted sulfamoyl or PO n H 2 where n is 2 or 3; X 3 is a divalent aliphatic hydrocarbon; R 3 is carboxyl, 5-tetrazolyl, SO. sub.3 H, PO. sub.2 H 2, PO 3 H 2 or haloalkylsulfamoyl; and the rings A and B independently of one another are substituted or unsubstituted; in free form or in salt form, can be prepared in a manner known per se and can be used, for example, as medicament active ingredients.